Insulet Corporation (PODD) is a Medical - Devices company in the Healthcare sector, currently trading at $201.49. It has a SharesGrow Score of 74/100, indicating a above average investment profile with 4 out of 7 criteria passed.
SharesGrow calculates the intrinsic value of PODD = $321.45 (+59.5% from the current price, the stock appears undervalued). Analyst consensus target is PODD = $357 (+77.3% upside).
Valuation: PODD trades at a trailing Price-to-Earnings (P/E) of 57.2 (S&P 500 average ~25) with a forward Price/Earnings-to-Growth (PEG) of 2.06.
Financials: revenue is $2.7B, +27.6%/yr average growth. Net income is $247M, growing at +1482.2%/yr. Net profit margin is 9.1% (thin). Gross margin is 71.6% (+9.9 pp trend).
Balance sheet: total debt is $1.1B against $1.5B equity (Debt-to-Equity (D/E) ratio 0.69, moderate). Current ratio is 2.78 (strong liquidity). Debt-to-assets is 32.9%. Total assets: $3.2B.
Analyst outlook: 35 / 49 analysts rate PODD as buy (71%) — strong consensus.
SharesGrow 7-Criteria breakdown: Value 42/100 (Partial), Growth 100/100 (Pass), Past 100/100 (Pass), Health 67/100 (Partial), Moat 80/100 (Pass), Future 85/100 (Pass), Income 45/100 (Partial).
